129 related articles for article (PubMed ID: 34580903)
1. A novel SERPINE1-FOSB fusion gene in pseudomyogenic hemangioendothelioma results in activation of intact FOSB and the PI3K-AKT-mTOR signaling pathway and responsiveness to sirolimus.
Ren J; Wang X; Zhou Y; Yue X; Chen S; Ding X; Zeng S; Jiang X; Liu X; Guo Q
J Dermatol; 2021 Dec; 48(12):1900-1906. PubMed ID: 34580903
[TBL] [Abstract][Full Text] [Related]
2. Penile pseudomyogenic hemangioendothelioma/epithelioid sarcoma-like hemangioendothelioma with a novel pattern of SERPINE1-FOSB fusion detected by RT-PCR--report of a case.
Ide YH; Tsukamoto Y; Ito T; Watanabe T; Nakagawa N; Haneda T; Nagai M; Yamanishi K; Hirota S
Pathol Res Pract; 2015 May; 211(5):415-20. PubMed ID: 25749627
[TBL] [Abstract][Full Text] [Related]
3. Expanding the Spectrum of Genetic Alterations in Pseudomyogenic Hemangioendothelioma With Recurrent Novel ACTB-FOSB Gene Fusions.
Agaram NP; Zhang L; Cotzia P; Antonescu CR
Am J Surg Pathol; 2018 Dec; 42(12):1653-1661. PubMed ID: 30256258
[TBL] [Abstract][Full Text] [Related]
4. Fusion of the Genes
Panagopoulos I; Lobmaier I; Gorunova L; Heim S
Cancer Genomics Proteomics; 2019; 16(4):293-298. PubMed ID: 31243110
[TBL] [Abstract][Full Text] [Related]
5. A novel SERPINE1-FOSB fusion gene results in transcriptional up-regulation of FOSB in pseudomyogenic haemangioendothelioma.
Walther C; Tayebwa J; Lilljebjörn H; Magnusson L; Nilsson J; von Steyern FV; Øra I; Domanski HA; Fioretos T; Nord KH; Fletcher CD; Mertens F
J Pathol; 2014 Apr; 232(5):534-40. PubMed ID: 24374978
[TBL] [Abstract][Full Text] [Related]
6. Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma.
van IJzendoorn DGP; Sleijfer S; Gelderblom H; Eskens FALM; van Leenders GJLH; Szuhai K; Bovée JVMG
Clin Cancer Res; 2018 Jun; 24(11):2678-2687. PubMed ID: 29511030
[No Abstract] [Full Text] [Related]
7. A novel CLTC-FOSB gene fusion in pseudomyogenic hemangioendothelioma of bone.
Bridge JA; Sumegi J; Royce T; Baker M; Linos K
Genes Chromosomes Cancer; 2021 Jan; 60(1):38-42. PubMed ID: 32749039
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous pseudomyogenic (epithelioid sarcoma-like) haemangioendothelioma FOSB immunohistochemistry demonstrating the SERPINE1-FOSB fusion gene.
Alegría-Landa V; Santonja C; Jo-Velasco M; Kutzner H; Requena L
J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):e550-e552. PubMed ID: 28622428
[No Abstract] [Full Text] [Related]
9. Vascular Tumor Recapitulated in Endothelial Cells from hiPSCs Engineered to Express the
van IJzendoorn DGP; Salvatori DCF; Cao X; van den Hil F; Briaire-de Bruijn IH; de Jong D; Mei H; Mummery CL; Szuhai K; Bovée JVMG; Orlova VV
Cell Rep Med; 2020 Dec; 1(9):100153. PubMed ID: 33377124
[TBL] [Abstract][Full Text] [Related]
10. FOSB is a Useful Diagnostic Marker for Pseudomyogenic Hemangioendothelioma.
Hung YP; Fletcher CD; Hornick JL
Am J Surg Pathol; 2017 May; 41(5):596-606. PubMed ID: 28009608
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic utility of FOSB immunohistochemistry in pseudomyogenic hemangioendothelioma and its histological mimics.
Sugita S; Hirano H; Kikuchi N; Kubo T; Asanuma H; Aoyama T; Emori M; Hasegawa T
Diagn Pathol; 2016 Aug; 11(1):75. PubMed ID: 27515856
[TBL] [Abstract][Full Text] [Related]
12. ZFP36-FOSB fusion defines a subset of epithelioid hemangioma with atypical features.
Antonescu CR; Chen HW; Zhang L; Sung YS; Panicek D; Agaram NP; Dickson BC; Krausz T; Fletcher CD
Genes Chromosomes Cancer; 2014 Nov; 53(11):951-9. PubMed ID: 25043949
[TBL] [Abstract][Full Text] [Related]
13. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
[TBL] [Abstract][Full Text] [Related]
14. Diverse clinical presentations of pseudomyogenic hemangioendothelioma associated with EGFL7::FOSB fusion: a second case.
Li B; Zhang C; Zhao L; Chen N; Hu Y; Li Z; Kang S; Blake A; Xiao S
Histopathology; 2024 Mar; 84(4):708-712. PubMed ID: 38012540
[No Abstract] [Full Text] [Related]
15. Primary pseudomyogenic haemangioendothelioma of the testis with a novel POTEI::FOSB gene fusion.
Gersmann AK; Haller F; Behnert N; Richter A; Stöhr R; Hartmann A; Ströbel P; Bremmer F
Histopathology; 2022 Sep; 81(3):411-414. PubMed ID: 35582841
[No Abstract] [Full Text] [Related]
16. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.
Sandhöfer N; Metzeler KH; Rothenberg M; Herold T; Tiedt S; Groiß V; Carlet M; Walter G; Hinrichsen T; Wachter O; Grunert M; Schneider S; Subklewe M; Dufour A; Fröhling S; Klein HG; Hiddemann W; Jeremias I; Spiekermann K
Leukemia; 2015 Apr; 29(4):828-38. PubMed ID: 25322685
[TBL] [Abstract][Full Text] [Related]
17. Abnormal Protein Glycosylation and Activated PI3K/Akt/mTOR Pathway: Role in Bladder Cancer Prognosis and Targeted Therapeutics.
Costa C; Pereira S; Lima L; Peixoto A; Fernandes E; Neves D; Neves M; Gaiteiro C; Tavares A; Gil da Costa RM; Cruz R; Amaro T; Oliveira PA; Ferreira JA; Santos LL
PLoS One; 2015; 10(11):e0141253. PubMed ID: 26569621
[TBL] [Abstract][Full Text] [Related]
18. High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors.
Smit DJ; Cayrefourcq L; Haider MT; Hinz N; Pantel K; Alix-Panabières C; Jücker M
Cells; 2020 Sep; 9(9):. PubMed ID: 32962206
[TBL] [Abstract][Full Text] [Related]
19. IL-22 induced cell proliferation is regulated by PI3K/Akt/mTOR signaling cascade.
Mitra A; Raychaudhuri SK; Raychaudhuri SP
Cytokine; 2012 Oct; 60(1):38-42. PubMed ID: 22840496
[TBL] [Abstract][Full Text] [Related]
20. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.
Martelli AM; Evangelisti C; Chiarini F; McCubrey JA
Oncotarget; 2010 Jun; 1(2):89-103. PubMed ID: 20671809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
